Clinical Trial Update: pCCLCHIM-p47 (Lentiviral Vector Transduced CD34 Plus Cells) in Patients With p47 Autosomal Recessive Chronic Granulomatous Disease (AR-CGD) [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating pCCLCHIM-p47 lentiviral vector-transduced CD34+ cells for p47 Autosomal Recessive Chronic Granulomatous Disease is currently…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Granulomatous Disease

Drugs mentioned

• pCCLCHIM-p47 (Lentiviral Vector Transduced CD34+ Cells) (pCCLCHIM-p47 lentiviral vector transduced CD34+ cells)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: p47, Autosomal Recessive | Phase 1, Phase 2 | Status: ENROLLING_BY_INVITATION